Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
[forminator_form id="25163"]

prnewswire.com+1.bloomberg.com.bloomberg.com+1.Isomorphic Labs, the AI drug discovery company run by Demis Hassabis, said on Tuesday, November 17, it has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital. The company is trying to move its first drug candidates into clinical trials. Andreessen Horowitz and several other new investors joined the round, and Alphabet continued to invest heavily, according to the company's announcement.reuters.com+1
The raise comes about six months after the company closed a $2.1 billion Series B led by Thrive Capital. Isomorphic, which was spun out of Google DeepMind in 2021, declined to share its valuation. Bloomberg had reported earlier this month that the round would value the company at about $50 billion.thenextweb.com+1
Isomorphic described the round as oversubscribed. Every existing investor took part, including Thrive Capital, MGX, Alphabet's venture arms GV and CapitalG, Temasek and the UK Sovereign AI Fund. Bloomberg reported that the round was led by "Silicon Valley titans".prnewswire.com+1
"Isomorphic Labs is building foundational technology for the future of medicine," said Konstantine Buhler, a partner at Sequoia. Greenoaks founder Neil Mehta called drug development "an optimization challenge of almost infinite scale".manilatimes.net
The company says its drug design engine, IsoDDE, has produced positive preclinical results in its own oncology and immunology programs and in work with partners, "setting the stage for clinical entry." It plans to use the money to keep developing its models, build a partner network focused on disease biology, and set up clinical development infrastructure.manilatimes.net
"What we're trying to build is a platform to do hundreds of drugs a year," Hassabis told Bloomberg. He said the company has more than 20 programs underway and plans to expand from small molecules into "pretty much all modalities," including biologics. Isomorphic's pharmaceutical partners include Eli Lilly , Novartis and Johnson & Johnson .thenextweb.com
The company's technology builds on DeepMind's Nobel Prize-winning AlphaFold protein-structure model. In January, Hassabis said Isomorphic expected to begin its first clinical trials by the end of 2026, a target that has only weeks left. No regulator has yet approved a drug designed by AI.tech.eu+1
"This round enables us to accelerate our progress," Hassabis said, including "driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients".manilatimes.net